Abstract

Objective. Previous experience in the treatment of multivessel coronary artery disease using PCI showed satisfactory short-term, but inferior long-term results in comparison to CABG. Certain groups of patients with multi-vessel disease treated with PCI may have long-term results equal to CABG. In the decision making process there is, apart from the angiographic finding, a need for careful evaluation of the patient's clinical state, treatment goals, previous knowledge and experience in order to reach the decision in the best interest of the patient. The aim of the study is to compare the outcome of PCI and TAXUS stent implantation with CABG in patients with multi-vessel coronary artery disease one year after the intervention. Methods. Our study included 114 patients in PCI group and 93 in CABG group, which were treated during 2004 and 2005. The outcome was expressed as the rate of MACCE which comprises death, reinfarction, CVI and reinterventions. Results. After one year follow-up composite MACCE rate was 17.5% in the PCI group and 14% in the CABG group (p=0.486). The rate of re-interventions between the PCI and CABG groups was 11,5% and 4.3% (p=0.064). There was no statistically significant difference between the incidence of MACCE (p=0.486) or between the frequency of reintervention between the groups (p=0.064). Conclusion. PCI with TAXUS stents implantation at one year follow up is equally effective as CABG in the treatment of multi-vessel coronary artery disease.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.